Adult T-cell leukemia

Disease ID:1225
Name:Adult T-cell leukemia
Associated with:0 target
1 immuno-relevant ligand
Synonyms
Adult T-cell leukemia/lymphoma | ATLL
Description
A T-cell leukemia that results in an abnormal elevation of lymphocytes.
Database Links
Disease Ontology: DOID:0050523

Targets

No target related data available for Adult T-cell leukemia

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
mogamulizumab
Immuno Disease Comments: An anti-CCR4 monoclonal antibody approved for relapsed or refractory adult T-cell leukemia/lymphoma.
Clinical Use: Approved first in Japan, for the treatment of relapsed or refractory adult T cell leukemia/lymphoma. The 2018 FDA approval allows Poteligeo® to be used as a treatment for two rare cutaneous T cell lymphomas; relapsed or refractory mycosis fungoides or Sézary syndrome (following at least one prior systemic therapy). In Europe the drug has EMA orphan designation for the treatment of cutaneous and peripheral T cell lymphomas. | View clinical data
Bioactivity Comments: Peptide sequence analysis of the heavy chain variable region of mogamulizumab matches sequence ID 9 from patent US7504104 [1], linking this antibody with clones Gal1LV1, Gal1LV2 or Gal1LV3. A graph of CCR4 binding by these antibody clones is provided in the patent, but no affinity value is specified. | View biological activity

References

Show »

1. Shitara K, Nakamura K, Hosaka E, Tanaka A, Koike M. (2009) Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens. Patent number: US7504104. Assignee: Kyowa Hakko Kogyo Co., Ltd. Priority date: 31/08/2001. Publication date: 17/01/2010.